Dublin, May 24, 2022 (GLOBE NEWSWIRE) -- The "Asia Pacific Insulin Syringes Market Size, Share & Industry Trends Analysis Report By Disease (Type 2 Diabetes and Type 1 Diabetes), By Syringe Size, By End User, By Country and Growth Forecast, 2021-2027" report has been added to ResearchAndMarkets.com's offering. The Asia Pacific Insulin Syringes Market is expected to witness market growth of 6.1% CAGR during the forecast period (2021-2027). Insulin syringes are widely used among diabetic patients for easier diabetes care, with around 40% of patients injecting insulin using these syringes. Insulin syringes are single-use disposable devices. This ensures that the needles are sterile, reducing the danger of infection from previously used needles. To minimize lipohypertrophy, or an abnormal fat accumulation under the skin, it's also necessary to rotate injection sites. With daily insulin shots, it's a frequent problem. Insulin is injected subcutaneously - that is, just under the skin - to avoid the needle puncturing muscle, which might alter the blood sugar levels. As the prevalence of diabetes rises, so will the need for insulin, which will have a favourable impact on market growth. Patients are increasingly using portable tools like insulin syringes for more convenient diabetes care, with roughly 40.0 percent of diabetics injecting insulin with syringes. In China, unhealthy diets and a lack of physical activity are contributing to rising rates of overweight and obesity, both of which are risk factors for Type 2 diabetes. In China, more than a third of adults are overweight, with 7% of persons being obese. Youngsters in China are also at danger of acquiring diabetes as a result of unhealthy lifestyles: more than 4 in 5 teenagers aged 11 to 17 do not receive adequate physical activity, and obesity in children are fast rising. As a result, increased diabetes cases will propel the Insulin Syringes Market forward. The China market dominated the Asia Pacific Insulin Syringes Market by Country 2020, and is expected to continue to be a dominant market till 2027; thereby, achieving a market value of $182 million by 2027. The Japan market is anticipated to grow a CAGR of 5.6% during (2021 - 2027). Additionally, The India market is expected to showcase a CAGR of 6.8% during (2021 - 2027). Based on Disease, the market is segmented into Type 2 Diabetes and Type 1 Diabetes. Based on Syringe Size, the market is segmented into 3/10 CC Syringe (0.3ml), 1/2 CC Syringe (0.5ml), 1CC Syringe (1ml) and Others. Based on End User, the market is segmented into Hospitals & Clinics, Homecare Settings, and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific. The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Hindustan Syringes & Medical Devices Ltd., Novo Nordisk A/S, Biocon Limited, Eli Lilly and Company, Abbott Laboratories, Becton, Dickinson and Company, Cardinal Health, Inc., Medline Industries, Inc., Terumo Corporation, and Nipro Corporation. Key Topics Covered: Chapter 1. Market Scope & Methodology Chapter 2. Market Overview 2.1 Introduction 2.1.1 Overview 2.1.1.1 Market Composition and Scenario 2.2 Key Factors Impacting the Market 2.2.1 Market Drivers 2.2.2 Market Restraints Chapter 3. Asia Pacific Insulin Syringes Market by Disease 3.1 Asia Pacific Type 2 Diabetes Market by Country 3.2 Asia Pacific Type 1 Diabetes Market by Country Chapter 4. Asia Pacific Insulin Syringes Market by Syringe Size 4.1 Asia Pacific 3/10 CC Syringe (0.3ml) Market by Country 4.2 Asia Pacific 1/2 CC Syringe (0.5ml) Market by Country 4.3 Asia Pacific 1CC Syringe (1ml) Market by Country 4.4 Asia Pacific Other Syringe Size Market by Country Chapter 5. Asia Pacific Insulin Syringes Market by End User 5.1 Asia Pacific Hospitals & Clinics Market by Country 5.2 Asia Pacific Homecare Settings Market by Country 5.3 Asia Pacific Others Market by Country Chapter 6. Asia Pacific Insulin Syringes Market by Country 6.1 China Insulin Syringes Market 6.1.1 China Insulin Syringes Market by Disease 6.1.2 China Insulin Syringes Market by Syringe Size 6.1.3 China Insulin Syringes Market by End User 6.2 Japan Insulin Syringes Market 6.2.1 Japan Insulin Syringes Market by Disease 6.2.2 Japan Insulin Syringes Market by Syringe Size 6.2.3 Japan Insulin Syringes Market by End User 6.3 India Insulin Syringes Market 6.3.1 India Insulin Syringes Market by Disease 6.3.2 India Insulin Syringes Market by Syringe Size 6.3.3 India Insulin Syringes Market by End User 6.4 South Korea Insulin Syringes Market 6.4.1 South Korea Insulin Syringes Market by Disease 6.4.2 South Korea Insulin Syringes Market by Syringe Size 6.4.3 South Korea Insulin Syringes Market by End User 6.5 Singapore Insulin Syringes Market 6.5.1 Singapore Insulin Syringes Market by Disease 6.5.2 Singapore Insulin Syringes Market by Syringe Size 6.5.3 Singapore Insulin Syringes Market by End User 6.6 Malaysia Insulin Syringes Market 6.6.1 Malaysia Insulin Syringes Market by Disease 6.6.2 Malaysia Insulin Syringes Market by Syringe Size 6.6.3 Malaysia Insulin Syringes Market by End User 6.7 Rest of Asia Pacific Insulin Syringes Market 6.7.1 Rest of Asia Pacific Insulin Syringes Market by Disease 6.7.2 Rest of Asia Pacific Insulin Syringes Market by Syringe Size 6.7.3 Rest of Asia Pacific Insulin Syringes Market by End User Chapter 7. Company Profiles 7.1 Hindustan Syringes & Medical Devices Ltd. 7.1.1 Company Overview 7.2 Novo Nordisk A/S 7.2.1 Company Overview 7.2.2 Financial Analysis 7.2.3 Segmental & Regional Analysis 7.2.4 Research & Development Expenses 7.2.1 Recent strategies and developments: 7.2.1.1 Acquisitions and Mergers: 7.3 Biocon Limited 7.3.1 Company Overview 7.3.2 Recent strategies and developments: 7.4 Eli Lilly and Company 7.4.1 Company Overview 7.4.2 Financial Analysis 7.4.3 Regional Analysis 7.4.4 Research & Development Expense 7.4.5 Recent Strategies and Developments: 7.4.5.1 Partnerships, Collaborations, and Agreements: 7.4.5.2 Product Launches and Product Expansions: 7.4.5.3 Approvals and Trials: 7.5 Abbott Laboratories 7.5.1 Company Overview 7.5.2 Financial Analysis 7.5.3 Segmental and Regional Analysis 7.5.4 Research & Development Expense 7.5.5 Recent strategies and developments: 7.5.5.1 Partnerships, Collaborations, and Agreements: 7.6 Becton, Dickinson and Company 7.6.1 Company Overview 7.6.2 Financial Analysis 7.6.3 Segmental and Regional Analysis 7.6.4 Research & Development Expense 7.6.5 Recent strategies and developments: 7.6.5.1 Approvals and Trials: 7.9 Terumo Corporation 7.9.1 Company Overview 7.9.2 Financial Analysis 7.9.3 Segmental Analysis 7.10. Nipro Corporation 7.10.1 Company Overview 7.10.2 Financial Analysis 7.10.3 Segmental and Regional Analysis 7.10.4 Research & Development Expenses For more information about this report visit https://www.researchandmarkets.com/r/tbltpq
As we move toward the end of Q2, it’s time to start thinking about earnings. Looking back at the quarter, analysts are predicting earnings growth of 8%, which may rise to 11% heading into next year. It’s a rosy picture, but it’s also not a sure thing. GDP contracted in Q1, by nearly 1.5%, and some estimates are showing 0% growth in Q2. Such results would meet the technical definition of a recession – and recession is hardly the usual environment to find robust earnings growth. Looking at current
Nuclear submarine supplier to be sold to US buyer after diplomatic row Russian default expected within days Retail sales volumes down 0.5pc in May FTSE 100 rises strongly Ambrose Evans-Pritchard: The pro-Brussels establishment is painting Brexit as an economic disaster to reverse it Sign up here for our daily business briefing newsletter
When you need another stream of income for retirement, you might consider an annuity. You purchase the annuity from an insurance company and receive payments back at a later date. Before buying an annuity, it's important to consider how much … Continue reading → The post How Much Does a $300,000 Annuity Pay Per Month? appeared first on SmartAsset Blog.
In this article, we will take a look at 10 value stocks to buy according to billionaire David Tepper. If you want to skip our discussion on Tepper’s history and his hedge fund’s performance, go directly to 5 Value Stocks to Buy According to Billionaire David Tepper. With a net worth of $16.7 billion, David […]
At current levels, investors need a 7% to 8% return just to preserve their wealth.
Tesla plant near Shanghai is going to shut down temporarily, according to reports. On Wednesday, Reuters reported that Tesla (ticker: TSLA) will shut down production in China for a couple of weeks at the start of July to upgrade equipment. Tesla didn’t return a request for comment.
As Netflix cuts costs to ease subscriber-loss pains, more jobs have been scrapped.
(Bloomberg) -- Shares of China’s electric-vehicle makers are trouncing global industry leader Tesla Inc., bolstered by Beijing’s consumption incentives and heavy dip-buying from investors.Most Read from BloombergSupreme Court Overturns Roe, Transforming Abortion-Rights FightStocks Roar Back With Best Week in a Month: Markets WrapJustice Kavanaugh Says States May Not Bar Travel to Obtain an AbortionProtest Latest: NY, DC Marches Grow as Justice’s Home TargetedEnding Roe Is Institutional Suicide f
Energy prices are high. But bargain-hunter Buffett continues to bet on big oil.
“Time is running out for cash-burning companies kept afloat with easy access to capital,” New Constructs CEO David Trainer said in a Thursday research note.
Shares of the specialty pharmaceutical company Bausch Health Companies (NYSE: BHC) are surging today in response to the news that Joseph Papa has resigned from the board of directors effective immediately. Over the past six years, Papa has been instrumental in lowering the company's sky-high debt and keeping it out of bankruptcy court. Bausch said in a statement Thursday evening that billionaire hedge fund manager John Paulson will fill the vacant board position.
At least seven people were injured after plane crash-landed and caught fire on Miami International Airport runway
This month we’ve received both good and bad news from the “single greatest predictor of future stock market returns.” It is a contrarian indicator, with higher equity allocations associated with lower subsequent market returns, and vice versa. According to a simple econometric model I constructed that bases its predictions on the historical correlation between the indicator and the stock market, the S&P 500’s real total return over the next decade will be minus 3.3% annualized.
In addition to summer beach reads by Elin Hilderbrand and Jenny Han, Jenny Mollen's debut fiction book, "City of Likes," makes the best sellers list.
Dividend stocks are the new darlings in S&P 500. But investors are getting burned on those stocks, too.
(Bloomberg) -- Chinese electric vehicle maker Nio Inc. said a test car crashed from the third floor of its headquarters in Shanghai, killing two people.Most Read from BloombergJuul’s Vaping Products Are Ordered Off the Market in the USElon Musk Says New Tesla Plants Are ‘Money Furnaces’ Losing BillionsThe World’s Bubbliest Housing Markets Are Flashing Warning SignsRecession Worries Boost Treasuries; Stocks Advance: Markets WrapJuul Soon to Be Ordered Off the Market by FDA, WSJ ReportsThe acciden
Despite bankruptcy fears, layoffs, and lawsuits, Elon Musk wants people to know about Tesla's recent American-made win.
The Dow Jones moved higher as yields fell. Tesla stock skidded after CEO Elon Musk voiced a warning. A Warren Buffett stock rose.
Peaky Blinders and Cobra producer Joe Donaldson has set an indie, Magic Hour Television, and signed a first-look deal with All3Media International and All3Media-owned drama house New Pictures. Donaldson will develop a slate, funded by All3 and its international arm, and partner with New Pictures co-founder and CEO Willow Grylls to produce scripted TV. Furthermore, Donaldson […]
Deep discounts on Apple devices have been popping up with increasing frequency lately. Today, however, there are some surprisingly impressive Apple deals at the nation’s top online retailers. In fact, the best Apple deals now have prices so low that it seems like a mistake! With Prime Day 2022 less than a month away, however, … The post Best early Prime Day Apple deals you can shop now appeared first on BGR.